Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2026-06-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于部分募集资金专项账户注销完成的公告
Capital/Financing Update Classification · 85% confidence The document is a corporate announcement detailing the status and cancellation of special bank accounts established to hold proceeds from a prior non‐public share issuance, including fundraising amounts, usage reallocations, and account closure procedures. It does not present full financial statements (so it is not an annual or interim report), nor is it a transcript, AGM material, or regulatory attestation. This is clearly an update on the company’s financing (management of issuance proceeds), fitting the Capital/Financing Update category.
2026-06-04 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement by Nanjing PharmaBlock Technology Co., Ltd. detailing the implementation of its 2025 annual equity distribution (cash dividend), including per-share dividend amounts, record date, ex-dividend date, distribution mechanics, and related parameters. It is clearly a dividend payment notice rather than a full financial report or other regulatory filing. Therefore, it matches the definition for Notice of Dividend Amount (DIV).
2026-06-03 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “2025年度股东会决议公告” and provides detailed AGM meeting logistics and vote tallies for each resolution of the 2025 Annual General Meeting. It is a formal announcement of shareholder vote results rather than the full AGM materials, financial report, or proxy statement. This corresponds to the Declaration of Voting Results & Voting Rights Announcements category (DVA).
2026-05-12 Chinese
药石科技2025年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a legal opinion letter issued by a law firm on the company’s 2025 Annual General Meeting. It provides detailed voting results for each resolution (number of shares for, against, abstaining, percentages) at the AGM. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-12 Chinese
2025年度募集资金存放、管理与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and usage of funds raised by the company through a specific stock issuance in 2020. It includes detailed financial figures, regulatory references to Chinese securities laws and Shenzhen Stock Exchange guidelines, and auditor and sponsor opinions on the fund usage. The document is titled as a "专项报告" (special report) on the 2025 fiscal year fundraising funds usage and management. It contains actual financial data, project investment details, changes in project implementation, and compliance statements. This type of document corresponds to a specialized report on capital raised and its usage, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report, audit report, or earnings release, nor is it a simple announcement or certification. Therefore, the correct classification is CAP with high confidence.
2026-04-21 Chinese
关于2026年度开展外汇衍生品交易预计及授权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its plan to conduct foreign exchange derivative transactions in the upcoming fiscal year 2026. It includes details about the purpose, investment amount, types of derivative products, risk analysis, risk control measures, and the approval process involving the board and audit committee. The document is relatively short (3199 characters) and primarily serves to inform shareholders and the public about the proposed derivative trading activities and the need for shareholder approval. It does not contain actual financial statements, quarterly or annual financial results, or detailed financial data. It is not a report but an announcement of a planned financial activity requiring shareholder authorization. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including derivative trading authorizations and risk management related to financial instruments.
2026-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.